Sorrento Therapeutics, Inc. (0L85.L)
| Chiusura precedente | 0,9925 |
| Aperto | 0,0000 |
| Denaro | 0,0000 x N/D |
| Lettera | 0,0000 x N/D |
| Min-Max giorno | 0,0000 - 0,0000 |
| Intervallo di 52 settimane | |
| Volume | |
| Media Volume | N/D |
| Capitalizzazione | 1,076M |
| Beta (5 anni mensile) | 1,96 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -1,5270 |
| Prossima data utili | N/D |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
- GlobeNewswire
Sorrento Issues “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock
SAN DIEGO, Jan. 29, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today posted a “Frequently Asked Questions” document under the “Investors” section of its website at www.sorrentotherapeutics.com regarding its recent dividend to Sorrento stockholders of shares of common stock of Scilex Holding Company held by Sorrento. The FAQs address questions regarding the details of the dividend, including the record date, payment date, dividend ratio, distribution of the sh
- GlobeNewswire
Scilex Holding Company Announces that its Majority Stockholder, Sorrento Therapeutics, Inc., has Issued an “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock
PALO ALTO, Calif., Jan. 29, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX) announced that its majority stockholder, Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today posted a “Frequently Asked Questions” document under the “Investors” section of its website at www.sorrentotherapeutics.com regarding its recent dividend to Sorrento stockholders of shares of common stock of Scilex Holding Company held by Sorrento. The FAQs address questions regarding the details of the di
- GlobeNewswire
Sorrento Releases Positive Results from a Phase 1b Study in China in COVID-19 Patients and is Ready for Pivotal Phase 3 trials with OVYDSO™ (STI-1558), an Oral Mpro Inhibitor as a Standalone Treatment for COVID-19 without the Need for Ritonavir Boosting
Topline safety, antiviral effectiveness and pharmacokinetic (PK) data from a Phase 1b Study in China are released from the single ascending dose (SAD) portion of the study with the doses from 300 mg to 2,000 mg in 32 healthy volunteers and the multiple ascending dose (MAD) portion of the study in 46 COVID-19 patients with 300 mg BID, 600 mg BID and 800 mg BID daily dosing for 7.5 days.Overall, STI-1558 was well-tolerated at all doses tested, with most subjects in both the SAD and MAD portions of
